Table 4 Univariate analysis of the association between potential prognostic factors and survival for all 165 patients with malignant pleural effusions
From: Important prognostic factors for survival in patients with malignant pleural effusion
Prognostic factors | Categories | Patients (n) | Median survival time (months) – (95% CI) | Hazard ratio (95% CI) | P value |
|---|---|---|---|---|---|
ECOG performance status | 0 | 9 | 55.0 (46.0-58.0) | 1.0 | < 0.0001* |
Status | 1 | 9 | 22.0 (22.0-27.0) | 1.67 (0.93-3.01) | Â |
2 | 19 | 18.0 (13.0-19.0) | 2.13 (1.24-3.63) | Â | |
3 | 47 | 7.0 (6.0-8.0) | 3.72 (2.26-6.11) | Â | |
4 | 81 | 1.0 (1.0-2.0) | 10.50 (5.96-18.50) | Â | |
Gender | Male | 77 | 3.0 (2.0-5.0) | 1.14 (0.80-1.61) | Â |
Female | 88 | 6.0 (4.0-7.0) | 1.0 | 0.4105 | |
Pleural fluid | <13.0 | 24 | 4.0 (2.0-6.0) | 1.0 | Â |
Neutrophils (%) | ≥13.0 | 25 | 4.0 (2.0-8.0) | 1.23 (0.70-2.16) | 0.4091 |
Pleural fluid glucose (mg/dL) | <96.0 | 37 | 3.0 (2.0-7.0) | 1.04 (0.66-1.64) | Â |
|  | ≥96.0 | 38 | 5.0 (3.0-6.0) | 1.0 | 0.8323 |
Pleural fluid LDH (U/L) | <589.0 | 36 | 6.0 (3.0-8.0) | 1.0 | Â |
|  | ≥589.0 | 36 | 3.5 (2.0-7.0) | 1.18 (0.74-1.88) |  |
Pleural fluid total | <75.5 | 24 | 4.5 (2.0-7.0) | 1.0 | 0.4247 |
lymphocytes (%) | ≥75.5 | 24 | 3.5 (2.0-7.0) | 1.14 (0.64-2.01) | 0.6040 |
Age (years) | <60 | 79 | 5.0 (3.0-7.0) | 1.0 | Â |
≥60 | 86 | 4.0 (3.0-6.0) | 1.08 (0.79-1.47) | 0.5618 | |
Pleural fluid total | <4.4 | 36 | 5.0 (2.0-6.0) | 1.0 | Â |
proteins (g%) | ≥4.4 | 39 | 5.0 (3.0-7.0) | 1.26 (0.80-2.00) | 0.2590 |
Histopathology | Positive | 83 | 6.0 (2.0-5.0) | 1.33 (0.97-1.81) | Â |
Negative | 82 | 4.0 (4.0-9.0) | 1.0 | 0.0429* | |
Cytology | Positive | 89 | 6.0 (4.0-8.0) | 1.25 (0.88-1.78) | Â |
Negative | 76 | 3.5 (2.0-5.0) | 1.0 | 0.0403* | |
Classification | Exudate | 70 | 4.0 (3.0-6.0) | 1.04 (0.44-2.43) | Â |
Transudate | 6 | 5.0 (1.0-8.0) | 1.0 | 0.9161 | |
Cancer site | Other | 155 | 4.0 (3.0-6.0) | 1.0 | Â |
Ovary | 10 | 21.0 (8.0-22.0) | 1.99 (1.23-3.22) | 0.0186* |